Outset Medical posts 5% revenue growth, adds board member

Outset Medical Inc. (NASDAQ: OM) reported unaudited revenue of $119.5 million for 2025, representing a 5% increase from $113.7 million in 2024. Fourth quarter revenue totaled $28.9 million.

The medical technology company, which develops dialysis equipment, reported year-end cash totaling $173 million, including restricted cash, cash equivalents and short-term investments. Net cash used in operations decreased to below $50 million in 2025 from $116 million in 2024.

More than 1,000 sites of care have implemented Outset's dialysis technology, performing approximately 1 million treatments annually and over 3 million cumulative treatments using the company's Tablo system, according to the company.

Outset appointed Karen N. Prange to its board of directors and Compensation Committee, replacing Andrea Saia who served since March 2021. Prange currently serves on the boards of AtriCure, Embecta and privately held WS Audiology, and works as a Senior Advisor to EQT Group.

Prange previously held executive positions at Henry Schein, where she served as Executive Vice President and CEO for the Global Animal Health, Medical and Dental Surgical Group. She also worked as Senior Vice President at Boston Scientific and President of its Urology and Pelvic Health business, and spent 17 years at Johnson & Johnson in various roles.

"We enter 2026 with a strong backlog, a growing pipeline of new opportunities," said Leslie Trigg, Chair and Chief Executive Officer.

The financial information is preliminary and unaudited, subject to change pending completion of year-end processes and preparation of audited financial statements for the fiscal year ended December 31, 2025.

You May Also Be Interested In

• Boeing names Ryan Shedd as new SVP and controller
• BIGG Digital Assets to rename as Surge Digital, consolidate shares
• Alzamend Neuro (ALZN) files for 98.4M share offering by selling stockholders